FANCF

Fanconi anemia group F protein

1,060 patent compounds predicted against FANCF, 947 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Rutin (SCHEMBL23243)	1.00	2/20
Rutin (SCHEMBL23244)	1.00	2/20
Rutin (SCHEMBL148590)	1.00	2/20
Rutin (SCHEMBL796642)	1.00	2/20
Rutin (SCHEMBL802819)	1.00	2/20
Rutin (SCHEMBL2017898)	1.00	2/20
Rutin (SCHEMBL5580506)	1.00	2/20
Rutin (SCHEMBL5580508)	1.00	2/20
Rutin (SCHEMBL5918715)	1.00	2/20
Rutin (SCHEMBL6552718)	1.00	2/20
Rutin (SCHEMBL8193625)	1.00	2/20
Rutin (SCHEMBL10285592)	1.00	2/20
Rutin (SCHEMBL13696392)	1.00	2/20
Rutin (SCHEMBL13696608)	1.00	2/20
Rutin (SCHEMBL14369486)	1.00	2/20
Rutin (SCHEMBL14952130)	1.00	2/20
Rutin (SCHEMBL15025698)	1.00	2/20
Rutin (SCHEMBL15029221)	1.00	2/20
Rutin (SCHEMBL15263233)	1.00	2/20
Rutin (SCHEMBL15591879)	1.00	2/20

Germline variants in FANCF on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full FANCF gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to FANCF by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Eltrombopag for People With Fanconi Anemia	PHASE2	ACTIVE_NOT_RECRUITING
Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors	PHASE2	COMPLETED
Prenatal Transplantation for Fetuses With Fanconi Anemia	PHASE1/PHASE2	NOT_YET_RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Gene Therapy for Fanconi Anemia, Complementation Group A	PHASE2	ACTIVE_NOT_RECRUITING
Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100	PHASE1/PHASE2	COMPLETED
M6620 (VX-970) in Selected Solid Tumors	PHASE2	COMPLETED
Efficacy and Safety of PARPi to Treat Pancreatic Cancer	PHASE2	COMPLETED
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy	PHASE2	RECRUITING
A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Olaparib in Treating Patients With Stage IV Pancreatic Cancer	PHASE2	COMPLETED
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission	PHASE1/PHASE2	COMPLETED
A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors	PHASE1	COMPLETED
Gene Therapy for the Treatment of Fanconi's Anemia Type C	PHASE1	COMPLETED
Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors	PHASE1	COMPLETED
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia	PHASE1	COMPLETED
Quercetin in Children With Fanconi Anemia; a Pilot Study	PHASE1	COMPLETED
Pilot Study of Etanercept (Enbrel) in Children With Fanconi Anemia	EARLY_PHASE1	COMPLETED
Corrective Exercise and Rehabilitation in Fanconi Anemia: A Case Study	nan	COMPLETED
Clinical Genetics Branch Eligibility Screening Survey	nan	NOT_YET_RECRUITING
Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma	nan	COMPLETED
Utility of a Urine Screening Tool for Vitamin D Deficiency in Infants and Toddlers	nan	COMPLETED
Cancer in Inherited Bone Marrow Failure Syndromes	nan	RECRUITING
Long-Term Follow-up of Subjects With Fanconi Anaemia Subtype A Treated With ex Vivo Gene Therapy	nan	ACTIVE_NOT_RECRUITING
Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base	nan	RECRUITING
Prognostic Significance of Mutation Type and Chromosome Fragility in Fanconi Anemia	nan	COMPLETED
Men at High Genetic Risk for Prostate Cancer	nan	RECRUITING
Stereo Photogrammetry Imaging in Normal Volunteers and Patients With Head and Facial Malformations	nan	COMPLETED
Microcephaly Genetic Deficiency in Neural Progenitors	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a FANCF binder may also engage these)

Protein	Name	Similarity
E1C7U0	—	0.997	E1C7U0 →
P50652	—	0.995	P50652 →
E1BLZ4	—	0.995	E1BLZ4 →
O35870	—	0.994	O35870 →
A6NJJ6	—	0.994	A6NJJ6 →
Q68DK2	—	0.994	Q68DK2 →
Q7TSF4	—	0.993	Q7TSF4 →
Q8BLY7	—	0.993	Q8BLY7 →
D4A8G9	—	0.993	D4A8G9 →
O19104	—	0.993	O19104 →
GEMIN4	Gem-associated protein 4	0.993	landscape →
Q499E6	—	0.992	Q499E6 →
Q80UW3	—	0.992	Q80UW3 →
Q6GQV0	—	0.992	Q6GQV0 →
P57680	—	0.992	P57680 →
Q80TT8	—	0.992	Q80TT8 →
Q5DU37	—	0.991	Q5DU37 →
Q9QXP4	—	0.991	Q9QXP4 →
Q9D3F7	—	0.991	Q9D3F7 →
Q8VHZ9	—	0.991	Q8VHZ9 →
D2H5P6	—	0.990	D2H5P6 →
Q96PX9	—	0.989	Q96PX9 →
Q9HCU8	—	0.989	Q9HCU8 →
Q8R239	—	0.988	Q8R239 →
Q91XA5	—	0.988	Q91XA5 →
A6H754	—	0.988	A6H754 →
Q8N6Y0	—	0.988	Q8N6Y0 →
A0A291NUI4	—	0.988	A0A291NUI4 →
Q9UJT2	—	0.988	Q9UJT2 →
Q86YV9	—	0.988	Q86YV9 →